论文部分内容阅读
目的:观察阿加曲班对急性脑梗死(ACI)患者血清白细胞介素8(IL-8)水平的影响。方法:开放随机对照研究,65例患者按1∶1∶1方法随机分成3组:对照组,治疗组A和治疗组B,3组均采用基础治疗,治疗组在基础治疗外合并应用阿加曲班,治疗组A阿加曲班60 mg·d-1溶解于溶液中静脉滴注,连续48 h治疗,治疗组B阿加曲班60 mg·d-1溶解于溶液中静脉滴注,连续48 h治疗后,随后阿加曲班10 mg溶解于溶液中静脉滴注,bid,连续5 d。入院后即刻(d0),第1,2,3,4,6,9,12天及入院后第4周,各抽空腹静脉血2 mL检测IL-8水平的变化。结果:阿加曲班可明显降低血清IL-8的水平(P<0.05),但比较应用阿加曲班2 d 60 mg·d-1和持续阿加曲班48 h后随即给予每次10 mg,bid,连续5 d,2组IL-8的变化曲线无差异(P>0.05)。结论:早期48 h应用大剂量(60 mg·d-1)阿加曲班可明显降低血清IL-8水平,但持续应用至1周比仅使用48 h不能更加降低血清IL-8水平。
Objective: To observe the effect of argatroban on serum interleukin 8 (IL-8) level in patients with acute cerebral infarction (ACI). Methods: Open randomized controlled study, 65 patients were randomly divided into three groups according to 1: 1: 1 method: the control group, treatment group A and treatment group B, 3 groups were treated with basic treatment, the treatment group in addition to basic treatment combined with Aga Curculigoid group, treatment group A argatroban 60 mg · d-1 dissolved in solution by intravenous infusion for 48 h treatment, the treatment group B argatroban 60 mg · d-1 dissolved in solution by intravenous drip, After 48 h of treatment, 10 mg of argatroban was then dissolved in solution for 5 days. Immediately after admission (d0), on the 1st, 2nd, 3rd, 4th, 6th, 9th and 12th days after admission and 4 weeks after admission, IL-8 levels were measured in 2 mL of fasting venous blood. Results: Argatroban significantly decreased the level of serum IL-8 (P <0.05). However, argatroban 2 days 60 mg · d-1 and argatroban 48 hours later were given 10 There was no difference between the two groups in the change curve of IL-8 for 5 consecutive days (P> 0.05). CONCLUSION: High dose (60 mg · d-1) argatroban can significantly reduce the level of serum IL-8 at 48 h. However, continuous application of argatroban at 48 h can not reduce the serum IL-8 level even after 48 h.